Altria Group Inc (MO-NYSE)

Size: px
Start display at page:

Download "Altria Group Inc (MO-NYSE)"

Transcription

1 March 20, 2015 Altria Group Inc (MO-NYSE) Current Recommendation SUMMARY DATA NEUTRAL Prior Recommendation Underperform Date of Last Change 08/12/2009 Current Price (03/19/15) $51.27 Target Price $ Week High $ Week Low $36.02 One-Year Return (%) Beta 0.51 Average Daily Volume (sh) 6,844,511 Shares Outstanding (mil) 1,969 Market Capitalization ($mil) $100,967 Short Interest Ratio (days) 1.80 Institutional Ownership (%) 59 Insider Ownership (%) 0 Annual Cash Dividend $2.08 Dividend Yield (%) Yr. Historical Growth Rates Sales (%) 0.2 Earnings Per Share (%) 8.0 Dividend (%) 8.3 using TTM EPS 19.9 using 2015 Estimate 18.3 using 2016 Estimate 16.9 Zacks Rank *: Short Term 1 3 months outlook 3 - Hold * Definition / Disclosure on last page SUMMARY Risk Level * Altria s fourth-quarter 2014 earnings of $0.66 missed the Zacks Consensus Estimate by 1.5%. However, earnings increased 16% year over year backed by strong performance of leading premium brands in the core tobacco category. Sales increased 4.7% year over year and beat the Zacks Consensus Estimate by 2.2%. We commend the company s growing market share in the e-cigarette category and efforts to adapt to the evolving consumer trends and develop less harmful alternative tobacco products. However, shift in demand from traditional tobacco products has dented volumes in the Smokeable segment. Higher fees associated with litigations and the FDA s anti-smoking campaigns are hurting profitability. Low, Type of Stock Large-Growth Industry Tobacco Zacks Industry Rank * 193 out of 267 ZACKS CONSENSUS ESTIMATES Revenue Estimates (In millions of $) Q1 Q2 Q3 Q4 Year (Mar) (Jun) (Sep) (Dec) (Dec) ,973 A 4,526 A 4,760 A 4,404 A 24,466 A ,008 A 4,571 A 4,753 A 4,613 A 24,522 A ,117 E 4,734 E 4,875 E 4,641 E 18,367 E ,718 E Earnings Per Share Estimates (EPS is operating earnings before non-recurring items, but including employee stock options expenses) Q1 Q2 Q3 Q4 Year (Mar) (Jun) (Sep) (Dec) (Dec) 2013 $0.54 A $0.62 A $0.65 A $0.57 A $2.38 A 2014 $0.57 A $0.65 A $0.69 A $0.66 A $2.57 A 2015 $0.62 E $0.72 E $0.76 E $0.70 E $2.80 E 2016 $3.03 E Projected EPS Growth - Next 5 Years % Zacks Investment Research, All Rights reserved S. Riverside Plaza, Chicago IL 60606

2 OVERVIEW Altria Group, Inc. (MO) was founded in 1919 and is headquartered at Richmond, VA. It is the holding company for Philip Morris USA, Inc. (PM USA), UST LLC (UST), John Middleton Inc. and Philip Morris Capital Corporation (PMCC). PM USA manufactures and sells cigarettes and certain smokeless products in the United States. UST manufactures and sells smokeless products and wine. John Middleton Inc. is a leading manufacturer of machine-made large cigars. PMCC is a financial company engaged primarily in leasing activities. Altria reports under the following segments on the basis of products: Smokeable Products: The segment, which comprises mainly of PM USA, sells major brands like Marlboro cigarettes, Virginia Slims cigarettes and Parliament cigarettes. Smokeless Tobacco: The segment was formed after the acquisition of UST and its smokeless tobacco business in Jan The smokeless products segment includes brands like Copenhagen, Skoal, Red Seal, Husky and Marlboro Snus, a PM USA spit-less smokeless tobacco product. Wine: The segment was formed after the acquisition of UST and its premium wine business Ste. Michelle. The main brands are Chateau Ste. Michelle and Columbia Crest. The company also owns wineries or distributes wines from several other wine regions and foreign countries. Financial Services: Altria holds investments in finance leases, principally in transportation (including aircraft), power generation and manufacturing equipment and facilities. REASONS TO BUY Strong Brand Portfolio: Altria s impressive brand portfolio of tobacco and wine products helps it to maintain its strong business momentum and generate decent profit. Its portfolio boasts popular names like Marlboro, Virginia Slims, Copenhagen, Skoal, Chateau Ste. Michelle and Columbia Crest. The company has been able to maintain leading positions in cigarettes with Marlboro, machine-made large cigars with Black & Mild and smokeless tobacco with Copenhagen and Skoal. PM USA, invests continuously in improving the brand architecture of Marlboro. In fiscal 2014 Marlboro expanded Southern Cut in the Gold family and Marlboro Edge in the Marlboro Black family. Moreover, in the same year, the company upgraded its shopping website marlboro.com which provides engaging content directly to adult smokers through mobile devices. These initiatives helped Marlboro gain a major leadership in the market in the first half of fiscal The company also has plans for further innovations like Marlboro Edge, Marlboro NXT and Eighty Threes which should help the brand maintain its position. In the Smokeless segment, Copenhagen Long Cut Wintergreen and Copenhagen Black have been popular among adult dippers. Skoal s smooth smokeless tobacco has also gained market share with Skoal X-tra and Skoal Classic. Altria is also implementing strategies to enhance Skoal's equity and carefully manage Skoal Classic price gaps in select geographies. These strategies are expected to boost the brand s share in the coming quarters. Equity Research MO Page 2

3 Adapting to Evolving Demands: There has been a general shift among consumers toward low-risk, smokeless tobacco products. In fiscal 2012, Altria collaborated with Okono A/S and developed innovative, non-combustible nicotine-containing products for adult tobacco consumers. Then in Jun 2012, Altria's subsidiary, Nu Mark launched Verve Discs, which acted as a substitute for the harmful tobacco derivatives. Verve Discs had a mint-flavored, chewable tobacco product containing tobaccoderived nicotine. Furthermore, Altria forayed into the popular category of e-cigarettes with the launch of MarkTen e- cigarettes in leading markets in Indiana in Aug 2013, which was nationwide expanded in the fourth quarter MarkTen became popular soon, as it is different from other e-cigarettes, as it can be used both as a disposable as well as a rechargeable device. In fact, MarkTen was ranked among the top e-vapor brands nationally based on market share as of 2014-end. In addition, the acquisition of e- vapor company Green Smoke Inc. in Feb 2014, boosted Altria s e-cigarette portfolio. Moreover, in an attempt to boost its unconventional tobacco products, Altria entered into a strategic agreement with Philip Morris. Under the agreement, Philip Morris will market Altria s MarkTen e- cigarettes internationally and the latter will distribute two of Philip Morris heated tobacco products in the U.S. The companies have also decided to partner on a regulatory engagement related to the products. The companies will also work on gaining shares as well as improving existing versions for the products. Such collaboration is encouraging as it will help the participating companies maintain market share amid declining volume and growing awareness against tobacco products. With regard to the agreement Nu Mark is expected to begin shipping products overseas for distribution by Philip Morris in fiscal Strong Pricing is the Growth Driver: Altria has always remained afloat amid declining volumes in the cigarette industry with the help of positive pricing. The company has combated unfavorable tax environment with price increases. Altria raised the prices of its cigarettes across all brands thrice in The regular market share gains by the company s brands despite repeated price increase in several markets shows the company s strong business model and strength of its key brands. We believe that pricing is going to be the key driver throughout fiscal 2015 as a possible decline in cigarette consumption will be offset by higher prices driving top-line growth. Enhances Shareholders Value: Altria consistently returns value to shareholders. The company s dividend payout ratio was the highest in the S&P Food Beverage and Tobacco Index. The company has already increased its dividend 48 times in the past 45 years, including the latest hike of 8.3% in Aug Since the spin-off of Philip Morris International in 2009, Altria has increased its dividend every year. Dividend has grown at a CAGR of 8.9% over the past five years since The company maintains a dividend payout ratio target of around 80% of its adjusted earnings per share. REASONS TO SELL Declining Volumes: Global demand for cigarettes has been affected by the anti-tobacco campaigns. Moreover, price increases and unfavorable excise tax environment have resulted in declining cigarette shipments. State weighted excise taxes per pack of cigarettes have grown at a compounded annual rate of 4.5% since So far in 2015, 19 state and local cigarette excise tax increase proposals have been introduced. Moreover, the possible merger between Reynolds and Philip Morris may pose a threat to Altria s volume and market share, going forward. Equity Research MO Page 3

4 Restrictions on Tobacco Consumption: The tobacco industry faces many challenges, which may pressure margins. Governments around the world are imposing restrictions on tobacco companies which, in turn, are lowering cigarette consumption. The U.S. Food and Drug Administration (FDA) has made it mandatory for tobacco companies to use precautionary labels on cigarette packets to dissuade customers from smoking. Moreover, The governments of U.K and Australia have imposed regulations for plain packaging for cigarettes Moreover, the European Union and the FDA have proposed a ban on menthol in accordance with the Tobacco Control Act which essentially states that menthol cigarettes have an adverse impact on public health and suggests the removal of menthol. Moreover, this ban will create a serious black market for these products, which would be incredibly detrimental to all tobacco companies. The regulatory authorities have imposed marketing and product regulations on e-cigarettes as well as there is not much scientific evidence to back their ability to help smokers quit or smoke less. Such a regulation is expected to adversely impact the e-cigarette business and top line of the company in the coming quarters. RECENT NEWS Altria Misses on Fourth Quarter Earnings, Offers Fiscal 2015 View Jan 30, 2015 Marlboro owner Altria Inc. s adjusted earnings of $0.66 per share in the fourth quarter of 2014 missed the Zacks Consensus Estimate of $0.67 by 1.5%. Earnings, however, exceeded the prior-year quarter figure by 16%, backed by strong performance of leading premium brands in the core tobacco category. Revenues and Margins Revenues, net of excise taxes, increased 4.7% to $4.6 billion backed by higher sales in all segments. Revenues beat the Zacks Consensus Estimate of $4.5 billion by 2.1%. Gross profit increased 9.1% from the year-ago quarter to $2.6 billion due to lower excise taxes levied on the company during the quarter. Operating income gained 6.3% year over year to $1.91 billion due to higher sales. Segment Details Smokeable Products Segment: Revenues increased 3.3% to $3.9 billion backed by higher pricing. Shipment volume, however, declined 1.6% to billion units from the prior-year quarter primarily due to overall decline in the industry. While cigarettes retail share gained 0.1 percentage point (pp) backed by higher gains in L7M and Discount brands, retail share for cigars declined 0.4 pp. Marlboro s retail share remained flat. Adjusted operating income increased 7.8% year over year to $1.71 billion on the back of higher pricing. Operating income margins inflated 1.8 pp to 43.9%. Smokeless Products: Revenues slipped 4.1% to $428 million due to lower volume. Smokeless products shipment volume increased 1% to million units as volume growth in Copenhagen was mostly offset by declines in Skoal and Other portfolio brands. Copenhagen brand s retail share gained 1.1 pp, while Skoal witnessed 0.7 pp decline in retail share primarily due to competitive activity. Equity Research MO Page 4

5 Furthermore, adjusted operating companies income remained flat year over year at $257 million as higher pricing and volumes were offset by higher promotional expenses made by the company. Operating companies income margins declined 2.5 pp to 60%. Wine: The segment s revenues went up 8.4% year over year to $207 million mainly due to higher pricing and improved shipments. Wine shipment volume increased 9.6% to 2.81 million units as higher volume in most of the brands was offset by 10.6% decline in Other brands. Adjusted operating companies income went up 17.8% to $53 million on the back of positive pricing. Operating income margins inflated 2.0 pp to 25.6%. Fiscal 2014 Results Adjusted earnings of $2.57 per share in 2014 were in line with the Zacks Consensus Estimate. Earnings, however, exceeded the prior-year quarter results by 8%, backed by strong performance by the core tobacco business and leading premium brands. Revenues, net of excise taxes, increased 1.6% year over year to $17.9 billion backed by higher sales in all the segments. Results were in line with the Zacks Consensus Estimate. Other Financial Details During the fourth quarter of fiscal 2014, Altria repurchased approximately 6.4 million shares for nearly $275 million. Altria s subsidiary Nu Mark LLC (Nu Mark) began shipping its MarkTen e-vapor products during the reported quarter. It completed the nationwide expansion of MarkTen e-vapor products, achieving distribution in over 130,000 retail stores. The company also issued $1 billion principal amount of 2.625% senior unsecured long-term notes due in Since the Philip Morris International Inc. spin-off in 2009, Altria increased its dividend every year. Moreover, the company has increased its dividend 48 times in the last 45 years. Outlook Altria issued the 2015 earnings guidance. The company expects earnings in the range of $2.75 to $2.80. The guidance reflects an increase of 7% to 9% from $2.57 in Altria expects that its 2015 full-year effective tax rate to be 35%. The company also expects capital expenditures in the range of $200 to $250 million. VALUATION Altria Group Inc. s current trailing 12-month earnings multiple is 19.9x, in line with the industry average. Over the last five years, Altria s shares have traded in the range of 11.2x to 21.9x trailing 12-month earnings. Based on 2015 earnings estimate of $2.80, the stock is trading at 18.3x, which is a 20.8% discount to the industry average of 23.1x. At the end of the fourth quarter of fiscal 2014, the P/B multiple of the stock was approximately 37.0x, representing a huge premium to the industry average of 9.5x. Equity Research MO Page 5

6 Currently Altria carries a Zacks Rank #3 (Hold). Our target price of $54.00 is based on approximately 19.3x our 2015 earnings estimate of $2.80. Key Indicators F1 F2 Est. 5-Yr EPS Gr% P/CF 5-Yr High 5-Yr Low ALTRIA GROUP (MO) Industry Average S&P PHILIP MORRIS (PM) IMPERIAL TOB GP (ITYBY) REYNOLDS AMER (RAI) LORILLARD CO (LO) TTM is trailing 12 months; F1 is 2015 and F2 is 2016, CF is operating cash flow P/B Last Qtr. P/B 5-Yr High P/B 5-Yr Low ROE D/E Last Qtr. Div Yield Last Qtr. EV/EBITDA ALTRIA GROUP (MO) Industry Average S&P Equity Research MO Page 6

7 Earnings Surprise and Estimate Revision History Equity Research MO Page 7

8 DISCLOSURES & DEFINITIONS The analysts contributing to this report do not hold any shares of MO. The EPS and revenue forecasts are the Zacks Consensus estimates. Additionally, the analysts contributing to this report certify that the views expressed herein accurately reflect the analysts personal views as to the subject securities and issuers. Zacks certifies that no part of the analysts compensation was, is, or will be, directly or indirectly, related to the specific recommendation or views expressed by the analyst in the report. Additional information on the securities mentioned in this report is available upon request. This report is based on data obtained from sources we believe to be reliable, but is not guaranteed as to accuracy and does not purport to be complete. Because of individual objectives, the report should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed herein are subject to change. This report is not to be construed as an offer or the solicitation of an offer to buy or sell the securities herein mentioned. Zacks or its officers, employees or customers may have a position long or short in the securities mentioned and buy or sell the securities from time to time. Zacks uses the following rating system for the securities it covers. Outperform- Zacks expects that the subject company will outperform the broader U.S. equity market over the next six to twelve months. Neutral- Zacks expects that the company will perform in line with the broader U.S. equity market over the next six to twelve months. Underperform- Zacks expects the company will under perform the broader U.S. Equity market over the next six to twelve months. The current distribution of Zacks Ratings is as follows on the 1133 companies covered: Outperform %, Neutral %, Underperform 9.0%. Data is as of midnight on the business day immediately prior to this publication. Our recommendation for each stock is closely linked to the Zacks Rank, which results from a proprietary quantitative model using trends in earnings estimate revisions. This model is proven most effective for judging the timeliness of a stock over the next 1 to 3 months. The model assigns each stock a rank from 1 through 5. Zacks Rank 1 = Strong Buy. Zacks Rank 2 = Buy. Zacks Rank 3 = Hold. Zacks Rank 4 = Sell. Zacks Rank 5 = Strong Sell. We also provide a Zacks Industry Rank for each company which provides an idea of the near-term attractiveness of a company s industry group. We have 264 industry groups in total. Thus, the Zacks Industry Rank is a number between 1 and 264. In terms of investment attractiveness, the higher the rank the better. Historically, the top half of the industries has outperformed the general market. In determining Risk Level, we rely on a proprietary quantitative model that divides the entire universe of stocks into five groups, based on each stock s historical price volatility. The first group has stocks with the lowest values and are deemed Low Risk, while the 5 th group has the highest values and are designated High Risk. Designations of Below-Average Risk, Average Risk, and Above-Average Risk correspond to the second, third, and fourth groups of stocks, respectively. Equity Research MO Page 8

Corcept Therapeutics, Inc.

Corcept Therapeutics, Inc. March 20, 2015 Corcept Therapeutics, Inc. NEUTRAL Current Recommendation Prior Recommendation Outperform Date of Last Change 03/20/2015 Current Price (03/19/15) $5.85 Target Price $6.25 (CORT-NASDAQ) SUMMARY

More information

(LO-NYSE) SUMMARY. Risk Level *

(LO-NYSE) SUMMARY. Risk Level * February 12, 2015 Lorillard Inc. (LO-NYSE) Current Recommendation SUMMARY DATA NEUTRAL Prior Recommendation Outperform Date of Last Change 05/22/2012 Current Price (02/11/15) $67.55 Target Price $71.00

More information

Orexigen Therapeutics, Inc.

Orexigen Therapeutics, Inc. February 27, 2015 Orexigen Therapeutics, Inc. Current Recommendation NEUTRAL Prior Recommendation Outperform Date of Last Change 06/06/2012 Current Price (02/26/15) $5.87 Target Price $6.25 SUMMARY DATA

More information

2014 CAGNY Investor Presentation. February 19, 2014

2014 CAGNY Investor Presentation. February 19, 2014 2014 CAGNY Investor Presentation February 19, 2014 Management Team Participants Howard Willard EVP and Chief Financial Officer, Altria Group, Inc. Dave Beran President and Chief Operating Officer, Altria

More information

Perrigo Company plc (PRGO-NYSE)

Perrigo Company plc (PRGO-NYSE) March 20, 2015 Perrigo Company plc (PRGO-NYSE) NEUTRAL Current Recommendation Prior Recommendation Outperform Date of Last Change 09/02/2012 Current Price (03/19/15) $170.37 Target Price $179.00 SUMMARY

More information

Medivation, Inc. (MDVN-NASDAQ)

Medivation, Inc. (MDVN-NASDAQ) March 19, 2015 Medivation, Inc. (MDVN-NASDAQ) NEUTRAL Current Recommendation Prior Recommendation Outperform Date of Last Change 03/25/2014 Current Price (03/18/15) $132.19 Target Price $139.00 SUMMARY

More information

Novo-Nordisk As (NVO-NYSE) Analyst Note

Novo-Nordisk As (NVO-NYSE) Analyst Note February 03, 2015 Novo-Nordisk As (NVO-NYSE) Analyst Note NEUTRAL Current Recommendation Prior Recommendation Outperform Date of Last Change 02/10/2014 Current Price (02/02/15) $44.73 Target Price $47.00

More information

Zacks Small-Cap Research

Zacks Small-Cap Research Zacks Small-Cap Research Sponsored Impartial - Comprehensive August 29, 2018 David Bautz, PhD 312-265-9471 dbautz@zacks.com scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 Opiant Pharmaceuticals,

More information

XXII: CTP Summarizes Scientific Case for Limiting Nicotine in Cigarettes. Company Update October 15, 2018 Industrial & Consumer Technology

XXII: CTP Summarizes Scientific Case for Limiting Nicotine in Cigarettes. Company Update October 15, 2018 Industrial & Consumer Technology Company Update Industrial & Consumer Technology (XXII - $2.81 - Buy) COMPANY NOTE JAMES McILREE, CFA, Senior Research Analyst, +1-646-465-9034 jmcilree@chardan.com Sales and trading 7 a.m. to 7 p.m. ET,

More information

Small-Cap Research. Diffusion Pharmaceuticals Inc. (DFFN-NASDAQ) DFFN: FDA Gives Final Guidance for Phase 3 Protocol for TSC in Inoperable GBM OUTLOOK

Small-Cap Research. Diffusion Pharmaceuticals Inc. (DFFN-NASDAQ) DFFN: FDA Gives Final Guidance for Phase 3 Protocol for TSC in Inoperable GBM OUTLOOK Small-Cap Research November 16, 2017 David Bautz, PhD 312-265-9471 dbautz@zacks.com scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 Diffusion Pharmaceuticals Inc. (DFFN-NASDAQ) DFFN: FDA Gives Final

More information

Small-Cap Research. VolitionRx Ltd (VNRX-NYSE) VNRX: More Positive Data in Colon/Lung Cancers. Anticipating Initial Launch This Year OUTLOOK

Small-Cap Research. VolitionRx Ltd (VNRX-NYSE) VNRX: More Positive Data in Colon/Lung Cancers. Anticipating Initial Launch This Year OUTLOOK Small-Cap Research February 2, 2016 Brian Marckx, CFA bmarckx@zacks.com Ph (312) 265-9474 scr.zacks.com 10 S. Riverside Plaza, Ste 1600, Chicago, IL 60606 VolitionRx Ltd (VNRX-NYSE) VNRX: More Positive

More information

Altria Group Inc. Ticker: MO

Altria Group Inc. Ticker: MO Altria Group Inc. Ticker: MO Business Description Altria Group Inc. through its subsidiaries manufactures and sells cigarettes, other tobacco products, machine-made large cigars and pipe tobacco. It also

More information

Small-Cap Research. VolitionRx Ltd (VNRX-OTC) VNRX: 938-Sample Set Supports Earlier Findings of High Accuracy in Colon Cancer Detection OUTLOOK

Small-Cap Research. VolitionRx Ltd (VNRX-OTC) VNRX: 938-Sample Set Supports Earlier Findings of High Accuracy in Colon Cancer Detection OUTLOOK Small-Cap Research September 12, 2014 Brian Marckx, CFA bmarckx@zacks.com Ph (312) 265-9474 scr.zacks.com 10 S. Riverside Plaza, Ste 1600, Chicago, IL 60606 VolitionRx Ltd (VNRX-OTC) VNRX: 938-Sample Set

More information

22nd Century Group, Inc. (XXII - $ Buy) Q1 Far Ahead of Expectations

22nd Century Group, Inc. (XXII - $ Buy) Q1 Far Ahead of Expectations Company Update Industrial & Consumer Technology 22nd Century Group, Inc. (XXII - $2.21 - Buy) COMPANY NOTE Estimate Change JAMES McILREE, CFA, Senior Research Analyst, +1-646-465-9034 jmcilree@chardan.com

More information

Small-Cap Research. Delmar Pharma (DMPI-NASDAQ) DMPI: Zacks Company Report OUTLOOK

Small-Cap Research. Delmar Pharma (DMPI-NASDAQ) DMPI: Zacks Company Report OUTLOOK Small-Cap Research May 25, 2017 Grant Zeng, CFA 312-265-9466 gzeng@zacks.com scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 Delmar Pharma (DMPI-NASDAQ) DMPI: Zacks Company Report DMPI: A New Phase

More information

Investor Day LA&C Region Lausanne, September 29, Jeanne Pollès President, Latin America & Canada Region

Investor Day LA&C Region Lausanne, September 29, Jeanne Pollès President, Latin America & Canada Region Investor Day LA&C Region Lausanne, September 29, 2016 Jeanne Pollès President, Latin America & Canada Region Agenda Regional Overview and Performance Regional Strategies Key Markets Conclusion 2 LA&C Regional

More information

Small-Cap Research. Celator Pharma (CPXX-NASDAQ)

Small-Cap Research. Celator Pharma (CPXX-NASDAQ) Small-Cap Research June 24, 2015 Grant Zeng, CFA 312-265-9466 gzeng@zacks.com scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 Celator Pharma (CPXX-NASDAQ) CPXX: Positive top line data reported for

More information

Q Investor Kit JANUARY-JUNE 2013

Q Investor Kit JANUARY-JUNE 2013 Q2 2013 Investor Kit JANUARY-JUNE 2013 1 Swedish Match reporting segments Snus and snuff - Swedish snus (Scandinavia and US) - Moist snuff (US) - SMPM International Other tobacco products - Cigars (US)

More information

Vontobel Viewpoints FDA New Direction on Tobacco Our Take

Vontobel Viewpoints FDA New Direction on Tobacco Our Take Quality Growth Boutique TM Vontobel Viewpoints On July 28, 2017, the new Commissioner of the U.S. Food and Drug Administration (FDA), Scott Gottlieb, surprised the markets by launching a consultation paper

More information

22nd Century Group, Inc. (XXII - $ Buy)

22nd Century Group, Inc. (XXII - $ Buy) Company Update Industrial & Consumer Technology 22nd Century Group, Inc. (XXII - $2.47 - Buy) COMPANY NOTE Estimate Change JAMES McILREE, CFA, Senior Research Analyst, +1-646-465-9034 jmcilree@chardan.com

More information

Q Investor Kit JANUARY-MARCH 2014

Q Investor Kit JANUARY-MARCH 2014 Q1 2014 Investor Kit JANUARY-MARCH 2014 Swedish Match reporting segments Snus and moist snuff Snus (Scandinavia and US) Moist snuff (US) SMPM International Other tobacco products Cigars (US) Chewing tobacco

More information

Small-Cap Research. Delmar Pharma (DMPI-OTCQB)

Small-Cap Research. Delmar Pharma (DMPI-OTCQB) Small-Cap Research February 24, 2015 Grant Zeng, CFA 312-265-9466 gzeng@zacks.com scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 Delmar Pharma (DMPI-OTCQB) DMPI: Ready to advance VAL-083 to pivotal

More information

Q Investor Kit JANUARY-MARCH 2013

Q Investor Kit JANUARY-MARCH 2013 Q1 2013 Investor Kit JANUARY-MARCH 2013 1 Swedish Match reporting segments Snus and snuff - Swedish snus (Scandinavia and US) - Moist snuff (US) - SMPM International Other tobacco products - Cigars (US)

More information

Q Investor Kit January December 2014

Q Investor Kit January December 2014 Q4 2014 Investor Kit January December 2014 Highlights for Q4 Sales up for all product areas and operating profit from product areas up by 8% Scandinavian hoarding for snus prior to tax increase in January

More information

SWEDISH MATCH RESULTS PRESENTATION Q3 2017

SWEDISH MATCH RESULTS PRESENTATION Q3 2017 SWEDISH MATCH RESULTS PRESENTATION Q3 2017 DISCLAIMER The information contained in this presentation has not been independently verified and is subject to change without notice and neither Swedish Match,

More information

Q Investor Kit JANUARY-JUNE 2014

Q Investor Kit JANUARY-JUNE 2014 Q2 2014 Investor Kit JANUARY-JUNE 2014 Swedish Match reporting segments Snus and moist snuff Snus (Scandinavia and US) Moist snuff (US) SMPM International Other tobacco products Cigars (US) Chewing tobacco

More information

Small-Cap Research. Oramed Pharmaceuticals (ORMP-NASDAQ) ORMP: Zacks Company Report OUTLOOK

Small-Cap Research. Oramed Pharmaceuticals (ORMP-NASDAQ) ORMP: Zacks Company Report OUTLOOK Small-Cap Research April 21, 2017 Grant Zeng, CFA 312-265-9421 gzeng@zacks.com scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 Oramed Pharmaceuticals (ORMP-NASDAQ) ORMP: Zacks Company Report ORMP:

More information

Global E-Cigarette Market- Industry Analysis & Outlook ( )

Global E-Cigarette Market- Industry Analysis & Outlook ( ) Global E-Cigarette Market- Industry Analysis & Outlook (2016-2020) ----------------------------------------- Executive Summary Electronic cigarettes, also known as E-cigarettes, electronic nicotine delivery

More information

RAI: Strong key-brands performance delivers 2Q13 profit growth; Company reaffirms full-year EPS guidance

RAI: Strong key-brands performance delivers 2Q13 profit growth; Company reaffirms full-year EPS guidance Contact: Investor Relations: Morris Moore (336) 741-3116 Media: Jane Seccombe (336) 741-5068 Reynolds American Inc. P.O. Box 2990 Winston-Salem, NC 27102-2990 RAI 2013-10 RAI: Strong key-brands performance

More information

Annual General Meeting of Shareholders of Philip Morris ČR a.s. Kutná Hora April 25, András Tövisi Chairman of the Board of Directors

Annual General Meeting of Shareholders of Philip Morris ČR a.s. Kutná Hora April 25, András Tövisi Chairman of the Board of Directors Annual General Meeting of Shareholders of Philip Morris ČR a.s. Kutná Hora April 25, 2014 András Tövisi Chairman of the Board of Directors Philip Morris ČR a.s. Annual General Meeting of Shareholders 2014

More information

scr.zacks.com 10 S. Riverside Plaza, Suite 1600, Chicago, IL (MBVX - Nasdaq) OUTLOOK ZACKS ESTIMATES

scr.zacks.com 10 S. Riverside Plaza, Suite 1600, Chicago, IL (MBVX - Nasdaq) OUTLOOK ZACKS ESTIMATES Small-Cap Research August 26, 2016 David Bautz, PhD 312-265-9471 dbautz@zacks.com scr.zacks.com 10 S. Riverside Plaza, Suite 1600, Chicago, IL 60606 MabVax Therapeutics Holdings, Inc. MBVX: Uplist to Nasdaq

More information

RAI reports strong 2Q16 performance and positive outlook; Accelerates returns to shareholders

RAI reports strong 2Q16 performance and positive outlook; Accelerates returns to shareholders Contact: Investor Relations: Bob Bannon (336) 741-3359 Media: Jane Seccombe (336) 741-5068 Reynolds American Inc. P.O. Box 2990 Winston-Salem, NC 27102-2990 RAI 2016-22 RAI reports strong 2Q16 performance

More information

Q2 INVESTOR KIT JANUARY-JUNE 2011

Q2 INVESTOR KIT JANUARY-JUNE 2011 Q2 INVESTOR KIT JANUARY-JUNE 2011 Swedish Match reporting segments Reporting segments following the transaction with STG on October 1, 2010 Snus and snuff - Swedish snus in Scandinavia and US - US moist

More information

Reynolds American to Acquire Lorillard

Reynolds American to Acquire Lorillard Reynolds American to Acquire Lorillard The Next Step in Transforming Tobacco July 15, 2014 Forward Looking Statements This presentation contains forward-looking information. Future results or events can

More information

Investor Day EEMA Region Lausanne, September 29, Drago Azinovic President, Eastern Europe, Middle East & Africa Region & PMI Duty Free

Investor Day EEMA Region Lausanne, September 29, Drago Azinovic President, Eastern Europe, Middle East & Africa Region & PMI Duty Free Investor Day EEMA Region Lausanne, September 29, 2016 Drago Azinovic President, Eastern Europe, Middle East & Africa Region & PMI Duty Free Agenda Overview and Key Results Vision and Strategic Pillars

More information

SWEDISH MATCH RESULTS PRESENTATION Q4 2018

SWEDISH MATCH RESULTS PRESENTATION Q4 2018 SWEDISH MATCH RESULTS PRESENTATION Q4 2018 DISCLAIMER The information contained in this presentation has not been independently verified and is subject to change without notice and neither Swedish Match,

More information

SNUS ON THE LOOSE: Big Tobacco s s latest attempt to make nicotine more attractive

SNUS ON THE LOOSE: Big Tobacco s s latest attempt to make nicotine more attractive SNUS ON THE LOOSE: Big Tobacco s s latest attempt to make nicotine more attractive U.S. Smokeless Tobacco Market Historically the preserve of smaller, specialized companies: Conwood U.S. U.S. Smokeless

More information

Small-Cap Research. Aevi Genomic Medicine (GNMX-NASDAQ) GNMX: SAGA Misses Primary Endpoint But Data-Within-Data Warrants Optimism OUTLOOK SUMMARY DATA

Small-Cap Research. Aevi Genomic Medicine (GNMX-NASDAQ) GNMX: SAGA Misses Primary Endpoint But Data-Within-Data Warrants Optimism OUTLOOK SUMMARY DATA Small-Cap Research March 27, 2017 Brian Marckx, CFA bmarckx@zacks.com Ph (312) 265-9474 scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 Aevi Genomic Medicine (GNMX-NASDAQ) GNMX: SAGA Misses Primary

More information

The Cigarette Market in Netherlands

The Cigarette Market in Netherlands The Cigarette Market in Netherlands Product Code: CG0148MR Published Date: April 2015 Report Price: US$ 975 (Single Copy) Synopsis Cigarettes in Austria report is a qualitative report providing extensive

More information

Imperial Brands Maximising Category Opportunities CAGNY February 2019

Imperial Brands Maximising Category Opportunities CAGNY February 2019 Imperial Brands Maximising Category Opportunities CAGNY 2019 21 February 2019 Disclaimer Certain statements in this announcement constitute or may constitute forward-looking statements. Any statement in

More information

scr.zacks.com 10 S. Riverside Plaza, Suite 1600, Chicago, IL (MBVX - Nasdaq) OUTLOOK ZACKS ESTIMATES

scr.zacks.com 10 S. Riverside Plaza, Suite 1600, Chicago, IL (MBVX - Nasdaq) OUTLOOK ZACKS ESTIMATES Small-Cap Research February 24, 2017 David Bautz, PhD 312-265-9471 dbautz@zacks.com scr.zacks.com 10 S. Riverside Plaza, Suite 1600, Chicago, IL 60606 MabVax Therapeutics Holdings, Inc. MBVX: Update on

More information

Designing a Smoke-Free Future

Designing a Smoke-Free Future Designing a Smoke-Free Future Morgan Stanley Global Consumer & Retail Conference New York, November 14, 2017 Jacek Olczak Chief Financial Officer Martin King President, Asia Region Forward-Looking and

More information

Walgreen Co. Reports Second Quarter 2010 Earnings Per Diluted Share of 68 Cents; Results Include 2 Cents Per Diluted Share of Restructuring Costs

Walgreen Co. Reports Second Quarter 2010 Earnings Per Diluted Share of 68 Cents; Results Include 2 Cents Per Diluted Share of Restructuring Costs Walgreen Co. Reports Second Quarter 2010 Earnings Per Diluted Share of 68 Cents; Results Include 2 Cents Per Diluted Share of Restructuring Costs Second quarter sales up 3.1 percent to record $17.0 billion

More information

Q Investor Kit January December 2015

Q Investor Kit January December 2015 Q4 2015 Investor Kit January December 2015 Summary and Overview 2 Q4 and full year 2015: Headline numbers Sales for the full year increased by 9 percent and for the fourth quarter by 5 percent. In local

More information

Small-Cap Research. Auspex Pharmaceuticals Inc. Buy Prior Recommendation. Current Recommendation. N/A Date of Last Change 11/11/2014

Small-Cap Research. Auspex Pharmaceuticals Inc. Buy Prior Recommendation. Current Recommendation. N/A Date of Last Change 11/11/2014 Small-Cap Research December 17, 2014 Jason Napodano, CFA 312-265-9421 jnapodano@zacks.com scr.zacks.com 10 S. Riverside Plaza, Suite 1600, Chicago, IL 60606 Auspex Pharmaceuticals Inc. ASPX SD-809 Hits

More information

Walgreens (WAG) Analyst: Juan Fabres Fall 2014

Walgreens (WAG) Analyst: Juan Fabres Fall 2014 Recommendation: Buy Target Price August 31, 2016: $77.57 1. Reasons for the Recommendation With the acquisition of Alliance Boots in Europe, Walgreens will be the first US pharmacy to operate retail stores

More information

Summary of Results for the First Half of FY2015/3

Summary of Results for the First Half of FY2015/3 Summary of Results for the First Half of FY2015/3 November 10, 2014 Tokyu Corporation (9005) http://www.tokyu.co.jp/ Contents Ⅰ.Executive Summary 2 Ⅱ.Conditions in Each Business 5 Ⅲ.Details of Financial

More information

RAI increases 3Q13 earnings on strong operating performance; tightens full-year EPS guidance

RAI increases 3Q13 earnings on strong operating performance; tightens full-year EPS guidance Contact: Investor Relations: Morris Moore (336) 741-3116 Media: Jane Seccombe (336) 741-5068 Reynolds American Inc. P.O. Box 2990 Winston-Salem, NC 27102-2990 RAI 2013-13 RAI increases 3Q13 earnings on

More information

January 30, 2018 Dow Wilson President and Chief Executive Officer

January 30, 2018 Dow Wilson President and Chief Executive Officer Acquisition of SIRTeX January 30, 2018 Dow Wilson President and Chief Executive Officer This presentation is intended exclusively for investors. It is not intended for use in Sales or Marketing. Forward-Looking

More information

Zacks Small-Cap Research Sponsored Impartial - Comprehensive

Zacks Small-Cap Research Sponsored Impartial - Comprehensive Zacks Small-Cap Research Sponsored Impartial - Comprehensive August 27, 2018 Grant Zeng, CFA 312-265-9466 gzeng@zacks.com scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 Atossa Genetics (ATOS-NASDAQ)

More information

ST. JUDE MEDICAL / THORATEC TRANSACTION HIGHLIGHTS July 22, 2015

ST. JUDE MEDICAL / THORATEC TRANSACTION HIGHLIGHTS July 22, 2015 ST. JUDE MEDICAL / THORATEC TRANSACTION HIGHLIGHTS July 22, 2015 1 FORWARD LOOKING STATEMENT This presentation contains forward-looking statements within the meaning of the Private Securities Litigation

More information

DIEBOLD NIXDORF AG AT GERMANY EQUITY FORUM

DIEBOLD NIXDORF AG AT GERMANY EQUITY FORUM November 28, 2017 DIEBOLD NIXDORF AG AT GERMANY EQUITY FORUM Dr. Jürgen Wunram Agenda Diebold Nixdorf AG History and shareholder structure Market trends, strategy and progress of integration Diebold Nixdorf

More information

APPENDIX A: Tobacco Marketing Expenditure Categories

APPENDIX A: Tobacco Marketing Expenditure Categories APPENDIX A: Tobacco Marketing Expenditure Categories The Federal Trade Commission (FTC) issues reports on annual cigarette and smokeless tobacco marketing expenditures, which are based on data from the

More information

(GALE-NASDAQ) OUTLOOK

(GALE-NASDAQ) OUTLOOK Small-Cap Research November 7, 2013 Grant Zeng, CFA 312-265-9466 gzeng@zacks.com scr.zacks.com 111 North Canal Street, Chicago, IL 60606 Galena Biopharma Inc. Galena: Reported sales from Abstral ahead

More information

Annual General Meeting of Shareholders of Philip Morris ČR a.s. Kutná Hora April 27, 2018

Annual General Meeting of Shareholders of Philip Morris ČR a.s. Kutná Hora April 27, 2018 Annual General Meeting of Shareholders of Philip Morris ČR a.s. Kutná Hora April 27, 2018 Árpád Könye Chairman of the Board of Directors Total Cigarette Market Czech Republic Total cigarette market down

More information

JT Group Consolidated Financial Results 2018 First Quarter Results

JT Group Consolidated Financial Results 2018 First Quarter Results JT Group Consolidated Financial Results 2018 First Quarter Results Naohiro Minami JT Group Chief Financial Officer *Please be reminded that the figures shown on these slides may differ from those shown

More information

For personal use only

For personal use only HY18 Result Presentation 13 February 2018 Dig Howitt Brent Cubis CEO & President CFO HY18 Result highlights Strong momentum across developed markets continues Developed market unit growth up 12% Strengthening

More information

Small-Cap Research. Celator Pharma (CPXX-NASDAQ)

Small-Cap Research. Celator Pharma (CPXX-NASDAQ) Small-Cap Research August 24, 2015 Grant Zeng, CFA 312-265-9466 gzeng@zacks.com scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 Celator Pharma (CPXX-NASDAQ) CPXX: Expecting overall survival data

More information

HILLENBRAND INDUSTRIES INC

HILLENBRAND INDUSTRIES INC HILLENBRAND INDUSTRIES INC FORM 8-K (Unscheduled Material Events) Filed 2/17/2004 For Period Ending 2/13/2004 Address 700 STATE ROUTE 46 E BATESVILLE, Indiana 47006-8835 Telephone 812-934-7000 CIK 0000047518

More information

SWEDISH MATCH INVESTOR KIT Q4 2016

SWEDISH MATCH INVESTOR KIT Q4 2016 SWEDISH MATCH INVESTOR KIT Q4 2016 A look at the quarter 2 Q4 HEADLINE BULLETS Sales increased by 6 percent to 3,957 MSEK (3,719) for the fourth quarter and by 7 percent to 15,551 MSEK (14,486) for the

More information

Competition in the Vaporized Nicotine Market and its Potential Impact on the Cigarette Market. David T. Levy Georgetown University

Competition in the Vaporized Nicotine Market and its Potential Impact on the Cigarette Market. David T. Levy Georgetown University Competition in the Vaporized Nicotine Market and its Potential Impact on the Cigarette Market David T. Levy Georgetown University The E-Cigarette Summit: Science, Regulation and Public Health Washington,

More information

Telekom Austria Group Results for the 1st Quarter May 27, 2003

Telekom Austria Group Results for the 1st Quarter May 27, 2003 Telekom Austria Group Results for the 1st Quarter 2003 May 27, 2003 1 Cautionary Statement This presentation contains certain forward-looking statements. Actual results may differ materially from those

More information

Zacks Small-Cap Research

Zacks Small-Cap Research Zacks Small-Cap Research October 26, 2017 Brian Marckx, CFA bmarckx@zacks.com Ph (312) 265-9474 scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 CytoSorbents Corporation (CTSO-NASDAQ) CTSO: Additional

More information

Global Smokeless Tobacco Market

Global Smokeless Tobacco Market Global Smokeless Tobacco Market ----------------------------------------------------- 2015 Executive Summary Smokeless tobacco is tobacco that is not burned. It is also known as chewing tobacco, oral tobacco,

More information

Forward Looking Information

Forward Looking Information Vital Signs, Inc. Forward Looking Information Except for historical information discussed, the statements made today are forward-looking statements that involve risks and uncertainties. Investors are cautioned

More information

Investor Day Lausanne, September 27, 2018

Investor Day Lausanne, September 27, 2018 Investor Day Lausanne, September 27, 2018 Jacek Olczak Chief Operating Officer OPERATING AROUND THE ADULT CONSUMER 2 Operating Around the Adult Consumer CC RRPs PMI Combustible Cigarette Performance Reduced-Risk

More information

MYnd Analytics, Inc. Update. Midtown Partners Research. Mental Health November 28, 2017

MYnd Analytics, Inc. Update. Midtown Partners Research. Mental Health November 28, 2017 Mental Health November 28, 2017 MYnd Analytics, Inc. OTC MYND We believe MYnd Analytics is commercializing a very valuable predictive technology in a field of medicine, mental disorders, where desicisions

More information

Investor Day EU Region Lausanne, June 26, Drago Azinovic President, European Union Region Philip Morris International

Investor Day EU Region Lausanne, June 26, Drago Azinovic President, European Union Region Philip Morris International Investor Day EU Region Lausanne, June 26, 2014 Drago Azinovic President, European Union Region Philip Morris International Agenda Strong Business Fundamentals Strategies for Growth Key Markets Concluding

More information

The Cigarette Market in Greece

The Cigarette Market in Greece The Cigarette Market in Greece Product Code: CG0145MR Published Date: April 2015 Report Price: US$ 975 (Single Copy) Synopsis Cigarettes in Greece report is a qualitative report providing extensive and

More information

FORM8-K HILLENBRAND,INC.

FORM8-K HILLENBRAND,INC. UNITEDSTATES SECURITIESANDEXCHANGECOMMISSION Washington,D.C.20549 FORM8-K CURRENTREPORT PursuanttoSection13or15(d)oftheSecuritiesExchangeActof1934 Date of Report (Date of earliest event reported): December18,2015

More information

Tobacco Insights May

Tobacco Insights May Tobacco Insights 2015 - May Product Code: TI0017MR Published Date: June 2015 Report Price: US$ 150 (Single Copy) Synopsis Tobacco Insights 2015 - May report is a qualitative report providing extensive

More information

The Economic Impact of Tobacco Control

The Economic Impact of Tobacco Control The Economic Impact of Tobacco Control Tobacco Industry SCARE Tactics Tobacco Industry SCARE tactics and misinformation deter governments from raising tobacco taxes and implementing effective tobacco control

More information

Morgan Stanley Global Consumer & Retail Conference New York, November 19, 2014

Morgan Stanley Global Consumer & Retail Conference New York, November 19, 2014 Morgan Stanley Global Consumer & Retail Conference New York, November 19, 2014 André Calantzopoulos Chief Executive Officer Philip Morris International Forward-Looking and Cautionary Statements This presentation

More information

scr.zacks.com 10 S. Riverside Plaza, Suite 1600, Chicago, IL (PRTX-OTCQB) UPDATE ZACKS ESTIMATES

scr.zacks.com 10 S. Riverside Plaza, Suite 1600, Chicago, IL (PRTX-OTCQB) UPDATE ZACKS ESTIMATES Small-Cap Research June 17, 2014 Jason Napodano, CFA David Bautz, PhD 312-265-9421 / jnapodano@zacks.com scr.zacks.com 10 S. Riverside Plaza, Suite 1600, Chicago, IL 60606 Protalex, Inc. PRTX: Analysis

More information

Our Focus on Driving Shareholder Value Begins Here

Our Focus on Driving Shareholder Value Begins Here Our Focus on Driving Shareholder Value Begins Here in the fields from which we source our tobacco leaf. In 2011 we purchased approximately 440 million kilograms of packed tobacco leaf. Our largest sources

More information

scr.zacks.com 111 North Canal Street, Chicago, IL (DEPO-NASDAQ) UPDATE ZACKS ESTIMATES

scr.zacks.com 111 North Canal Street, Chicago, IL (DEPO-NASDAQ) UPDATE ZACKS ESTIMATES Small-Cap Research December 19, 2013 Jason Napodano, CFA 312-265-9421 jnapodano@zacks.com scr.zacks.com 111 North Canal Street, Chicago, IL 60606 Depomed Inc. (DEPO-NASDAQ) DEPO: Another Fine Deal For

More information

Value creation through profitable growth Handelsbanken Nordic Large Cap Seminar, Stockholm 2016 Anders Lonning-Skovgaard, CFO

Value creation through profitable growth Handelsbanken Nordic Large Cap Seminar, Stockholm 2016 Anders Lonning-Skovgaard, CFO Value creation through profitable growth Handelsbanken Nordic Large Cap Seminar, Stockholm 2016 Anders Lonning-Skovgaard, CFO Coloplast has four business areas all with global sales presence Group revenue

More information

1Q Fornebu, April 29, 2015 Luis Araujo and Svein Stoknes

1Q Fornebu, April 29, 2015 Luis Araujo and Svein Stoknes 1Q 2015 Fornebu, April 29, 2015 Luis Araujo and Svein Stoknes Forward-Looking Statements and Copyright This Presentation includes and is based, inter alia, on forward-looking information and statements

More information

SUMMARY. Risk Level * ,214 A ,583 A ,674 E ,710 E

SUMMARY. Risk Level * ,214 A ,583 A ,674 E ,710 E February 6, 2015 Roche Holding AG Current Recommendation Prior Recommendation Neutral Date of Last Change 02/06/2015 Current Price (02/05/15) $33.81 Target Price $31.00 UNDERPERFORM SUMMARY (RHHBY-OTC)

More information

1Q2017 法人說明會 Jun. 9, 2017

1Q2017 法人說明會 Jun. 9, 2017 1Q2017 法人說明會 Jun. 9, 2017 FE group business Span over 10 major industries Own over 240 companies Established in 1937 9 public listed companies in Taiwan and HK Petrochemical & energy Polyester & synthetic

More information

Lars Dahlgren. President and CEO

Lars Dahlgren. President and CEO Lars Dahlgren President and CEO 1 Summing up 2013 Sales in line with last year but decreasing profits Sales +1% Operating profit -5% Earnings per share 13.63 SEK (14.33) Financially challenging year but

More information

Annual Shareholders Meeting

Annual Shareholders Meeting Annual Shareholders Meeting February 8, 2018 Dow R. Wilson, President and Chief Executive Officer Forward-Looking Statements Except for historical information, this presentation contains forward-looking

More information

Business Update. Reynolds American Inc. May 16, 2016

Business Update. Reynolds American Inc. May 16, 2016 Business Update Reynolds American Inc. May 16, 2016 1 Agenda Overview Susan Cameron President and Chief Executive Officer, RAI Operating companies business and brand highlights Debra Crew President and

More information

Investor Presentation

Investor Presentation ASX:THC B u i l d i n g a M e d i c i n a l C a n n a b i s B u s i n e s s Investor Presentation November 2017 DISCLAIMER The material in this presentation (material) is not and does not constitute an

More information

OUTLOOK FOR U.S. TOBACCO. Tom Capehart Agricultural Economist Economic Research Service U.S. Department of Agriculture

OUTLOOK FOR U.S. TOBACCO. Tom Capehart Agricultural Economist Economic Research Service U.S. Department of Agriculture Outlook 98 For Release: Tuesday February 24, 1998 OUTLOOK FOR U.S. TOBACCO Tom Capehart Agricultural Economist Economic Research Service U.S. Department of Agriculture The outlook for U.S.-grown tobacco

More information

FY2016 1H Results. Cookpad Inc.

FY2016 1H Results. Cookpad Inc. FY2016 1H Results Cookpad Inc. 1 1H Highlights Premium Service -Premium Service revenue increased by 39.6% YoY. -Number of premium members grew by 12.0% YoY to exceed 1.85 million. Advertising -Advertising

More information

Hyundai Motor Company 1 st Quarter 2011 Business Results. April 28, 2011

Hyundai Motor Company 1 st Quarter 2011 Business Results. April 28, 2011 Hyundai Motor Company 1 st Quarter 2011 Business Results April 28, 2011 Cautionary Statement with Respect to Forward-Looking Statements In the presentation that follows and in related comments by Hyundai

More information

Category ADVICE. For Tobacconists Only.

Category ADVICE. For Tobacconists Only. 2018 For Tobacconists Only www.bestway.co.uk www.batleys.co.uk MARKET INSIGHT Availability of best selling brands is absolutely critical 1 in 4 adult smokers would leave the store without making a purchase

More information

Zacks Small-Cap Research

Zacks Small-Cap Research Zacks Small-Cap Research Sponsored Impartial - Comprehensive May 15, 2018 David Bautz, PhD 312-265-9471 dbautz@zacks.com scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 Opiant Pharmaceuticals, Inc.

More information

Small-Cap Research. VolitionRx Ltd (VNRX-NYSE) VNRX: Large U.S. Study Comes Cheap and Could Support Eventual Asymptomatic FDA Filing OUTLOOK

Small-Cap Research. VolitionRx Ltd (VNRX-NYSE) VNRX: Large U.S. Study Comes Cheap and Could Support Eventual Asymptomatic FDA Filing OUTLOOK Small-Cap Research July 31, 2017 Brian Marckx, CFA bmarckx@zacks.com Ph (312) 265-9474 scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 VolitionRx Ltd (VNRX-NYSE) VNRX: Large U.S. Study Comes Cheap

More information

Visionary Private Equity Group is Pleased to Announce its Investment in MEDITE Cancer Diagnostics

Visionary Private Equity Group is Pleased to Announce its Investment in MEDITE Cancer Diagnostics Dear VPEG Limited Partner, We hope this investor update finds you well. We're pleased to share with you an important update below on the following: Visionary Private Equity Group is Pleased to Announce

More information

RESPONSE FROM ALTRIA:

RESPONSE FROM ALTRIA: RESPONSE FROM ALTRIA: FDA Regulation of Tobacco http://www.altria.com/en/cms/about_altria/federal_regulation_of_tobacco/default.aspx?src=top_nav http://www.fda.gov/tobaccoproducts/default.htm The Food

More information

NOVO NORDISK. Analyst: Recommendation: HOLD DATE: Industry: Drug manufacturers

NOVO NORDISK. Analyst: Recommendation: HOLD DATE: Industry: Drug manufacturers NOVO NORDISK Analyst: Recommendation: HOLD DATE: 11.11.2015 Industry: Drug manufacturers Share price 375,00 DKK Homepage www.novonordisk.com Ticker NVO Number of shares (000) 2.563.800 Target price 406,14

More information

JTI Switzerland. JTI Schweiz 3

JTI Switzerland. JTI Schweiz 3 JTI Schweiz 3 Who we are 300 employees JTI has been manufacturing tobacco products in the Wiggertal area for over 45 years. The local market organization and the production facility in Dagmersellen (canton

More information

America s Most Wanted Tobacco Villains The Usual Suspects, New Villains and Emerging Threats

America s Most Wanted Tobacco Villains The Usual Suspects, New Villains and Emerging Threats America s Most Wanted Tobacco Villains The Usual Suspects, New Villains and Emerging Threats The United States has made enormous progress in reducing youth smoking, with the smoking rate among high school

More information

The Dental Corporation Opportunity

The Dental Corporation Opportunity The Dental Corporation Opportunity for Practice Principals. It s the perfect professional collaboration. You focus on dentistry, we look after the paperwork. In recognition of what you, the Practice Principal,

More information

Nielsen: Tobacco 'All Channel' Data 1/27

Nielsen: Tobacco 'All Channel' Data 1/27 February 6, 2018 : Tobacco 'All Channel' Data 1/27 Marlboro Volume & Share Pressures Continue Tobacco Cig Industry Pricing Continues to Offset Vol Weakness As Headwind from CA $2/pk Cig Excise Tax Continues

More information

scr.zacks.com 10 S. Riverside Plaza, Suite 1600, Chicago, IL UPDATE ZACKS ESTIMATES

scr.zacks.com 10 S. Riverside Plaza, Suite 1600, Chicago, IL UPDATE ZACKS ESTIMATES Small-Cap Research November 14, 2014 Jason Napodano, CFA 312-265-9421 jnapodano@zacks.com scr.zacks.com 10 S. Riverside Plaza, Suite 1600, Chicago, IL 60606 Matinas BioPharma Holdings, Inc. (MTNB-OTCQB)

More information

Small-Cap Research. Atossa Genetics (ATOS-NASDAQ) OUTLOOK

Small-Cap Research. Atossa Genetics (ATOS-NASDAQ) OUTLOOK Small-Cap Research December 24, 2014 Grant Zeng, CFA 312-265-9466 gzeng@zacks.com scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 Atossa Genetics ATOS: Focused pure play breast care company with

More information

DelMar Pharmaceuticals Inc. (OTCQX: DMPI, Target Price: $5.75)

DelMar Pharmaceuticals Inc. (OTCQX: DMPI, Target Price: $5.75) Equity Healthcare / Biotechnology Update (December 3, 2015) DelMar Pharmaceuticals Inc. (OTCQX: DMPI, Target Price: $5.75) DelMar Pharmaceuticals, Inc. ( DelMar, OTCQX: DMPI) is a clinical stage biotechnology

More information